<DOC>
	<DOCNO>NCT00859404</DOCNO>
	<brief_summary>The study aim evaluate efficacy safety oglemilast treatment stable mild moderate persistent asthma . The study involve two week run period . This placebo control study . One four treatment arm placebo . The duration treatment 12 week .</brief_summary>
	<brief_title>A Clinical Study Oglemilast Patients With Mild Moderate Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Eligibility Criteria : Adult patient physiciandocumented diagnosis chronic , stable , persistent , mild moderate asthma ( clinical symptom document reversibility airway obstruction , FEV1 60 % 85 % predict value ) . The following criterion must meet randomisation visit : At least 80 % compliance singleblind placebo runin period FEV1 60 % 85 % predict value Without asthma exacerbation runin period Reversibility : patient require demonstrate ≥ 12 % increase FEV1 ( absolute improvement FEV1 least 200mL ) ≥ 10 min 15 minute inhalation 400 μg salbutamol via spacer Any symptom score ≥ 1 least 4 last 7 day runin Use salbutamol symptom relief &gt; 2 occasion least 4 last 7 day runin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Mild moderate persistent asthma</keyword>
</DOC>